Journal of the American Society of Nephrology, Vol 7, 924-929, Copyright © 1996 by American Society of Nephrology

REGULAR ARTICLES

Lupus nephritis in children: a longitudinal study of prognostic factors and therapy

N Baqi, S Moazami, A Singh, H Ahmad, S Balachandra and A Tejani
Department of Pediatrics, State University of New York Health Science Center at Brooklyn, NY 11203, USA.

There are only a few studies in the pediatric literature that have analyzed risk factors for renal failure in childhood lupus nephritis. This study reviewed the outcome of 56 children (4 to 18 yr of age) with lupus nephritis seen at the authors' institution over a 27-yr period (1965 to 1992), in relation to risk factors and therapy. All children underwent percutaneous renal biopsy before the institution of therapy. From 1965 to 1987, treatment for Class III and IV lupus nephritis consisted of high-dose pulse methylprednisolone, 500 mg daily for 10 days, followed by oral prednisone. From 1987 to 1992, IV cyclophosphamide was given monthly for 6 months and then every 3 months for a period of 3 yr for patients with Class III and Class IV disease. Of 56 children, 42% had Class IV and 21% had Class III histology at onset. The mean follow-up period was 4 yr and ranged from 0.5 to 20.3 yr. Life-table analysis showed that the cumulative proportion of patients surviving was 82.8% at 5 yr and 67.7% at 10 yr. Renal survival was 44.4% at 5 yr and 29% at 10 yr, after the initial diagnosis of lupus nephritis was made. Age at diagnosis, race, sex, initial serum creatinine level, and the presence of proteinuria, hypertension, and DNA antibody titers were reviewed with respect to disease progression, as was the histological class at diagnosis. The effect of the different therapies was also examined. Univariate analysis revealed a significant association of progression to ESRD with an elevated serum creatinine level (P = 0.021), decreased C3 complement (P = 0.024), hypertension (P = 0.053), and histological classification of Class IV lupus nephritis (P = 0.031). Multivariate analysis demonstrated that progression to ESRD was independently associated with an initial Class IV histology (relative risk, 1.78; P < 0.003), hypertension at presentation (relative risk, 1.67; P < 0.003), and a low C3 complement level in conjuction with a high creatinine level (relative risk, 1.52; P < 0.028). Among children with lupus nephritis, those with Class IV disease, hypertension, high creatinine levels, and low C3 complement levels at the time of diagnosis are at increased risk for ESRD. Initial histological classification of lupus nephritis was the most reliable prognostic factor for disease progression. This study was unable to detect a difference in outcome for the two treatment groups.

This article has been cited by other articles:

				S. D. Marks, S. J. Williams, K. Tullus, and N. J. Sebire Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in paediatric lupus nephritis Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3521 - 3526. [Abstract] [Full Text] [PDF]

				L. Ramirez Gomez, O Uribe Uribe, O Osio Uribe, H Grisales Romero, M. Cardiel, D Wojdyla, B. Pons-Estel, and on behalf of the Grupo Latinoamericano de Estudio Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children Lupus, June 1, 2008; 17(6): 596 - 604. [Abstract] [PDF]

				C. H. Cramer II, M. Mills, R. P. Valentini, W. E. Smoyer, H. Haftel, and P. D. Brophy Clinical presentation and outcome in a cohort of paediatric patients with membranous lupus nephritis Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3495 - 3500. [Abstract] [Full Text] [PDF]

				C.A.A. Silva and H.I. Brunner Review: Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus Lupus, August 1, 2007; 16(8): 593 - 599. [Abstract] [PDF]

				B. Ranchin and S. Fargue Review: New treatment strategies for proliferative lupus nephritis: keep children in mind! Lupus, August 1, 2007; 16(8): 684 - 691. [Abstract] [PDF]

				A Mak, C C Mok, W P Chu, C H To, S N Wong, and T C Au Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups Lupus, January 1, 2007; 16(1): 28 - 34. [Abstract] [PDF]

				I. Kozyro, I. Perahud, S. Sadallah, A. Sukalo, L. Titov, J. Schifferli, and M. Trendelenburg Clinical Value of Autoantibodies Against C1q in Children With Glomerulonephritis Pediatrics, May 1, 2006; 117(5): 1663 - 1668. [Abstract] [Full Text] [PDF]

				H I Brunner, A Bishnoi, A C Barron, L J Houk, A Ware, Y Farhey, A B Mongey, C F Strife, T B Graham, and M H Passo Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus Lupus, April 1, 2006; 15(4): 198 - 206. [Abstract] [PDF]

				F Perfumo and A Martini Lupus nephritis in children Lupus, January 1, 2005; 14(1): 83 - 88. [Abstract] [PDF]

				J. R. MacGowan, S. Ellis, M. Griffiths, and D. A. Isenberg Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999 Rheumatology, September 1, 2002; 41(9): 981 - 987. [Abstract] [Full Text] [PDF]

				K Takada, G G Illei, and D T Boumpas Cyclophosphamide for the treatment of systemic lupus erythematosus Lupus, March 1, 2001; 10(3): 154 - 161. [Abstract] [PDF]

				W. Egner The use of laboratory tests in the diagnosis of SLE J. Clin. Pathol., June 1, 2000; 53(6): 424 - 432. [Full Text] [PDF]

				J M Gloor Lupus nephritis in children Lupus, November 1, 1998; 7(9): 639 - 643. [Abstract] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673